Lenvatinib Pill
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hepatocellular Carcinoma
Conditions
Hepatocellular Carcinoma
Trial Timeline
Feb 2, 2022 → Oct 2, 2026
NCT ID
NCT05113186About Lenvatinib Pill
Lenvatinib Pill is a phase 2 stage product being developed by Eisai for Hepatocellular Carcinoma. The current trial status is active. This product is registered under clinical trial identifier NCT05113186. Target conditions include Hepatocellular Carcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05113186 | Phase 2 | Active |
Competing Products
20 competing products in Hepatocellular Carcinoma